Immunotherapy against tau tangles in Alzheimer’s mouse models
Published 15 July 2009
New insights into how a Phase III Alzheimer’s drug might work were among the advances in potential therapies targeting two abnormal brain proteins – beta amyloid and phosphorylated tau - at ICAD.
'Immunotherapy is an important and exciting avenue for dementia research. Unlike the previously reported development of an amyloid vaccine, this new preliminary research has produced antibodies that target the faulty tau protein. Introduction of these antibodies may prevent tangles from forming in nerve cells in the brain. Early results have shown some promise but this is preliminary research and some technical challenges need to be overcome before this study can be translated into drug treatments for people with dementia.'Professor Clive Ballard
Director of Research
Alzheimer's Society
Ends
Notes to editors
- Alzheimer's Society researchers at ICAD are available for interview and comment on request.
- The International Conference on Alzheimer's Disease is held in Vienna from 11 - 16 July. Please visit ICAD for further information.
- One in three people over 65 will die with dementia
- Alzheimer's Society research shows that 700,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051.
- Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them.
- Alzheimer's Society works in England, Wales and Northern Ireland
- Alzheimer's Society needs to raise money to help people live well with
dementia today and for research to find a cure for tomorrow. You can
donate now by calling 0845 306 0898 or visiting alzheimers.org.uk
- Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk